Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Natl. Cancer Inst.

Title: Journal of the National Cancer Institute

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1460-2105

ISSN (Print): 0027-8874

Publication date (Electronic): Jun 01 2017

Volume: 109

Issue: 6

Affiliations

[1 ] Affiliations of authors: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia (CKL, LD, SL, IM, VG); Cancer Care Centre, St. George Hospital, Sydney, Australia (CKL); Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong, China (YLW); Division of Thoracic Surgery, Department of Surgery (TM), and Department of Medical Oncology (KM, MF), Kinki University Faculty of Medicine, Osaka-Sayama, Japan; Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan (AI); Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Barcelona, Spain (RR); Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China (CZ); Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand (ST); School of Medicine, The University of Norte Dame, Sydney, Australia (SL); Department of Statistics, Macquarie University, Sydney, Australia (IM); Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University (YKT, CHY); Albert Einstein College of Medicine, Jacobi Medical Center, NY (RJG); Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, China (TM).

Article

Publisher Item ID: 2966513

DOI: 10.1093/jnci/djw279

PubMed ID: 28376144

SO-VID: 0cb5e709-60bc-4fcd-8b50-b9e20767ca4f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 104

See all cited by